Recombinant Human Plasminogen Activator Inhibitor-1 (PAI-1)
| Code | Size | Price |
|---|
| LEI-P169-10ug | 10 ug | £517.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
Ambient
Storage:
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Further Information
Format:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.5 with no calcium, magnesium, or preservatives.
Formulation:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.5 with no calcium, magnesium, or preservatives.
Long Description:
Plasminogen Activator Inhibitor-1 (PAI-1, Serpin E1) is a member of the serpin family of serine protease inhibitors and is the primary inhibitor of urokinase and tissue plasminogen activator (tPA) (1-2). It is also a major regulator of fibrinolysis and an important component of the acute phase response, the coordinated systemic reaction of an organism to tissue injury (3). PAI-1 is expressed predominantly in adipose, liver and vascular tissues and is also produced by certain tumor cells. It can also specifically bind vitronectin (VTN) to form a stable active complex with an increased circulatory half life relative to free PAI-1 (4). Elevated levels of PAI-1 are associated with obesity, diabetes and cardiovascular disease, and increased production of PAI-1 is induced by various obesity related factors such as TNFα, glucose, insulin, and very-low-density lipoprotein. The obesity related elevation of PAI-1 levels along with the consequential deficiency in plasminogen activators, can lead directly to increased risk of thrombosis and other coronary diseases. Accordingly, PAI-1 has been implicated as an important molecular link between obesity and coronary disease (5). PAI1 deficiency may represent an inherited autosomal recessive bleeding disorder (6).
Purity:
>95% by SDS-PAGE and analyzed by silver stain.
Target:
PAI-1
References
1. Ginsburg, D. et al. (1996) Blood 87:4718
2. Declerck, P. J. et al. (1996) Biochem. 35:7474
3. Gelehrter, T. D. et al. (1996) J. Cell. Physiol. 168:648
4. Schroeck, F. et al. (2003) Biol. Chem. 383:1143
5. De Taeye, B. et al. (2005) Curr. Opin. Pharmacol. 5:149
6. Reilly, T. M. et al. (1994) Blood Coagul. Fibrinol. 5:73
Related Products
| Product Name | Product Code | Supplier | Human PAI-1 ELISA Development Kit | LEI-P298 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant Human PAI-1 | LEI-P301 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||